Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 known ✓ | P49768 | 3/20 | 0.36 |
| ▸ | PSEN2 known ✓ | P49810 | 3/20 | 0.36 |
| ▸ | APH1B known ✓ | Q8WW43 | 3/20 | 0.36 |
| ▸ | NCSTN known ✓ | Q92542 | 3/20 | 0.36 |
| ▸ | APH1A known ✓ | Q96BI3 | 3/20 | 0.36 |
| ▸ | PSENEN known ✓ | Q9NZ42 | 3/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | WNT3A | P56704 | 5/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16606159 | 0.98 | AAK1 (0.48) | AAK1DYRK1AMAP4K4WNT3APDE3B | |
| Bicarbonate SCHEMBL28852218 | 0.91 | AAK1 (0.44) | AAK1DYRK1AWNT3APSEN1PSEN2 | |
| SCHEMBL19997549 | 0.84 | DYRK1A (0.47) | AAK1DYRK1AMAP4K4WNT3APDE3B | |
| SCHEMBL24767561 | 0.83 | AAK1 (0.48) | AAK1DYRK1AMAP4K4WNT3APDE3B | |
| SCHEMBL29393867 | 0.83 | AAK1 (0.48) | AAK1DYRK1AMAP4K4WNT3APDE3B | |
| SCHEMBL16593240 | 0.83 | DYRK1A (0.46) | AAK1DYRK1AMAP4K4WNT3APDE3B | |
| SCHEMBL11508291 | 0.79 | IDO1 (0.34) | — | |
| SCHEMBL13036114 | 0.76 | DYRK1A (0.53) | AAK1DYRK1AMAP4K4WNT3APDE3B | |
| SCHEMBL16606145 | 0.74 | AAK1 (0.49) | AAK1DYRK1AMAP4K4PDE3BPDE3A | |
| SCHEMBL22001270 | 0.73 | MAP4K4 (0.50) | AAK1DYRK1AMAP4K4WNT3APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489237-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3489237-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3052496-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-10072005-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-09-11 | — | — | US | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-9926312-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-20160244445-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| EP-3052496-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049574-A1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-09 | — | — | WO | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072005-B2 | 4-azaindole derivatives | CHRM1, CHRM4, CHRM2 | PSEN1 58/4885PSEN2 60/4885APH1B 882/4885 |
| US-20160244445-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | PSEN1 58/4885PSEN2 60/4885APH1B 882/4885 |
| US-20180208593-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | PSEN1 58/4885PSEN2 60/4885APH1B 882/4885 |
| US-20150094328-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | PSEN1 58/4885PSEN2 60/4885APH1B 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.